Eli Lilly and Company

Sr. Director, Therapeutic Research Technology

Chester, Maryland, United States

Not SpecifiedCompensation
Expert & Leadership (9+ years)Experience Level
Full TimeJob Type
UnknownVisa
Healthcare, Biotechnology, PharmaceuticalsIndustries

Requirements

Candidates must possess a strong blend of biopharma research expertise, mastery of OMICS technologies, and the ability to translate scientific requirements into scalable IT solutions. Experience in architecting enterprise-wide technology strategies, championing digital initiatives, and building forward-looking technology roadmaps is essential. Proven experience in defining and delivering OMICS data capabilities, including scRNA-seq, spatial transcriptomics, proteomics, CRISPR, and PerturbSeq technologies, is required. A deep understanding of FAIR data principles and experience in establishing scalable, cloud-native infrastructure for data acquisition, processing, and analysis are necessary. The role demands leadership experience in managing multidisciplinary teams, applying Agile methodologies, and fostering innovation. Strategic partnership experience with industry leaders and academic institutions, along with vendor selection and negotiation skills, is also required. Candidates must be adept at managing multi-million dollar budgets and staying abreast of industry trends.

Responsibilities

The Sr. Director, Therapeutic Research Technology will orchestrate IT transformation and digital innovation across Neuroscience, Diabetes & Obesity, Oncology, and Immunology therapeutic areas. They will partner with R&D leadership to architect IT strategies that accelerate drug discovery and ensure data infrastructure and digital capabilities evolve ahead of scientific innovation. Responsibilities include implementing comprehensive IT strategies aligned with scientific priorities, championing digital initiatives for competitive advantage, and building technology roadmaps. The role involves collaborating with scientific partners to define and deliver OMICS data capabilities, advocating for FAIR data principles, and designing product visions for therapeutic area-specific data platforms. Additionally, the Sr. Director will establish scalable cloud-native infrastructure, lead high-performing teams, manage product development lifecycles using Agile methodologies, foster a culture of innovation, and drive clear communication. They will cultivate strategic relationships with technology partners and academic institutions, evaluate and integrate emerging technologies, lead vendor selection and negotiations, and manage budgets to enhance value and innovation.

Skills

IT Strategy
Digital Innovation
Biopharma Research
OMICS Technologies
Data Infrastructure
Drug Discovery
Therapeutic Areas
Neuroscience
Diabetes
Obesity
Oncology
Immunology
R&D Leadership
IT Solutions
Scientific Requirements

Eli Lilly and Company

Develops and delivers prescription medicines globally

About Eli Lilly and Company

Eli Lilly and Company is a global pharmaceutical company that focuses on discovering, developing, and delivering medicines to improve health. The company has a long history of scientific achievements, including the creation of insulin, the first life-saving treatment for diabetes. Lilly's operations involve extensive research and development to create new medications and enhance existing ones, ensuring they are safe and effective. Their products are primarily prescription medicines sold to healthcare providers for various medical conditions, including diabetes, cancer, and pain management. What sets Lilly apart from its competitors is its strong commitment to ethical practices and the protection of its products from counterfeiting. The company's goal is to enhance lives through innovative medical solutions while maintaining high standards of quality and ethics.

Indianapolis, IndianaHeadquarters
1876Year Founded
$1,180.1MTotal Funding
IPOCompany Stage
Biotechnology, HealthcareIndustries
10,001+Employees

Risks

Competition from Novo Nordisk's Ozempic may impact tirzepatide's market share.
Potential construction delays in Indiana could affect GLP-1 drug production timelines.
Regulatory challenges may hinder Kisunla's expansion in new Alzheimer's markets.

Differentiation

Eli Lilly's rich history includes the first life-saving insulin treatment.
Lilly's strategic partnerships enhance its position in neurodegenerative disease treatments.
FDA approval of Zepbound opens new therapeutic markets for sleep disorder treatments.

Upsides

Lilly's $9 billion complex in Indiana boosts GLP-1 drug production capacity.
Kisunla's approval in China expands Lilly's Alzheimer's treatment market in Asia.
Collaboration with EVA Pharma enhances Lilly's reputation as socially responsible.

Land your dream remote job 3x faster with AI